Software-guided insulin dosing improves intrapartum glycemic management in women with diabetes mellitus

American Journal of Obstetrics and Gynecology
Cheryl DinglasHye J Heo

Abstract

During labor, maintenance of maternal euglycemia is critical to decrease the risk of neonatal hypoglycemia and associated morbidities. When continuous intravenous insulin infusion is needed, standardized insulin dosing charts have been used for titration of insulin to maintain glucose in target range. The GlucoStabilizer software program (Indiana University Health Inc, Indianapolis, IN) is a software-guided insulin dosing system that calculates the dose of intravenous insulin that is needed based on metabolic parameters, target glucose concentration, and an individual's response to insulin. Although this tool has been validated and shown to reduce both hypoglycemia and errors in critical care settings, the utility of this software has not been examined in obstetrics. The purpose of this study was to determine whether the use of intravenous insulin dosing software in women with pregestational or gestational diabetes mellitus that requires intrapartum insulin infusion can improve the rate of glucose concentration in target range (70-100 mg/dL; 3.9-5.5 mmol/L) at the time delivery. We performed a retrospective cohort study comparing laboring patients with diabetes mellitus that required insulin infusion who were dosed by standard ...Continue Reading

Citations

Jan 23, 2020·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Anna Y GroysmanStanislaw Klek
Jan 15, 2019·Journal of Diabetes Science and Technology·Pedro D Salinas, Carlos E Mendez
Jan 1, 2020·Journal of Diabetes and Metabolic Disorders· KusnantoHidayat Arifin
Oct 30, 2020·Journal of Diabetes Science and Technology·Kristen KulasaKevin Box
Nov 10, 2020·Current Diabetes Reports·Preethika S EkanayakeKristen Kulasa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Related Papers

Indian Journal of Endocrinology and Metabolism
Pramila Kalra, Manjunath Anakal
American Journal of Obstetrics and Gynecology
Juana A Flores-Le RouxJuan F Cano
© 2022 Meta ULC. All rights reserved